Protocol Ledger

NCT07239336 · Phase II · RECRUITING

Study of DONQ52 in Active Celiac Disease

Interventional Phase II clinical trial protocol NCT07239336 sponsored by Roche / Genentech in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-16 Enrollment: 92 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07239336
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)92 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07239336
Protocol FieldVerified Registry Value
NCT IdentifierNCT07239336
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment92 participants (ESTIMATED)
Registered Start Date2025-12-16
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI